Tirzepatide (GLP-1 T): A Research Peptide Overview

Tirzepatide — listed in our catalog as GLP-1 T — is a dual-agonist research peptide that has drawn significant attention in metabolic research. This overview explains its mechanism, the formats available, and how it differs from single-agonist compounds.

What is tirzepatide?

Tirzepatide is a synthetic peptide that acts as a dual GIP and GLP-1 receptor agonist. By engaging two incretin receptors at once, it is studied as a distinct mechanism compared with single GLP-1 agonists like semaglutide.

Research pathways

  • Dual GIP / GLP-1 receptor signaling research.
  • Metabolic and glucose-regulation research models.
  • Comparative incretin studies alongside semaglutide and retatrutide.

Formats & doses

GLP-1 T is available in lyophilized vials from 10 mg up to 60 mg, and in pre-reconstituted activated solutions across a wide range of concentrations:

Browse all options in the GLP-1 research series.

How it differs from semaglutide and retatrutide

The incretin family is studied along a spectrum of receptor targets: semaglutide (GLP-1 S) is a single GLP-1 agonist, tirzepatide (GLP-1 T) adds GIP for dual action, and retatrutide (GLP-1 R) adds glucagon for triple action. See our semaglutide overview for the single-agonist comparison.

Handling, reconstitution & purity

Reconstitute lyophilized vials with bacteriostatic water per our reconstitution guide, or choose an activated format — see lyophilized vs. activated. All vials are ≥98% HPLC-verified, with documentation on the Quality & COA page.

Manufacturing & Quality

Alpha Biologix manufactures GLP-1 T (tirzepatide) to pharmaceutical-grade manufacturing standards. Every batch is verified to ≥98% HPLC purity, tested by independent third-party laboratories, and backed by a Certificate of Analysis (COA) available on request — so researchers know exactly what's in the vial.

All products and information are provided for laboratory and research use only. Not for human or veterinary use, diagnostic, or therapeutic application. No medical claims are made.

Back to blog